Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol ADAM12 contributors: mct/ - updated : 04-01-2017
HGNC name ADAM metallopeptidase domain 12
HGNC id 190
corresponding disease(s)
Other morbid association(s)
TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
tumoral     --other  
aberrantly expressed in breast cancer patient urine, and increased urinary levels correlate with breast cancer progression
tumoral     --over  
in gastric carcinoma
constitutional     --over  
in osteoarthritic cartilage and enhances IGF1-mediated chondrocyte proliferation by degradation of insulin-like growth factor-binding protein IGFBP5
constitutional     --over  
fivefold upregulated in the nonhealing edge of chronic ulcers compared to healthy skin
tumoral     --low  
hypomethylated in Triple-negative breast cancer (TNBC)
Susceptibility to late-onset Alzheimer disease
Variant & Polymorphism other interaction between the ADAM12 and SH3PXD2A genes may confer susceptibility to late-onset Alzheimer disease
Candidate gene
  • for rapid diagnostic of cancer (detection of urinary ADAM 12 may prove useful in the development of noninvasive diagnostic and prognostic tests for breast and perhaps other cancers)
  • can be detected in the urine of breast and bladder cancer patients, and its levels have been shown to correlate with disease status, stage, and cancer risk
  • Marker
  • urinary MMP9/LCN2 and ADAM12 are potential noninvasive biomarkers for gastric cancer, including early-stage disease
  • serum BSG and ADAM12 values and urine ADAM12 values may be useful markers in prostate cancer
  • is a promising marker for the diagnosis of complete spontaneous abortion and ectopic pregnancy in symptomatic women, and under certain conditions, ADAM12 can diagnose ectopic pregnancy and spontaneous abortion before an ultrasonographic detection of the conditions
  • ADAM12L may serve as a novel marker and/or a novel therapeutic target in breast tumor-initiating cells (BTICs)
  • ADAM12 hypomethylation could be a poor outcome biomarker in Triple-negative breast cancer (TNBC)
  • Therapy target
    may represent a potential therapeutic target in breast cancer
    treatment of patients with the heparin analog CaPPS may promote ADAM12 degradation of IGFBP 3 and stimulate chondrocyte proliferation in osteoarthritic cartilage
    ADAM12L might be potential targets of esophageal carcinoma for anti-metastasis therapy
    topical ADAM12 inhibitors may therefore prove useful for the treatment of chronic wounds
    potential therapeutic target in Triple-negative breast cancer (TNBC